Identification of a domain that mediates association of platelet-activating factor acetylhydrolase with high density lipoprotein

被引:50
作者
Gardner, Alison A. [1 ]
Reichert, Ethan C. [1 ]
Topham, Matthew K. [1 ,2 ]
Stafforini, Diana M. [1 ,2 ]
机构
[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA
[2] Univ Utah, Dept Internal Med, Salt Lake City, UT 84112 USA
关键词
D O I
10.1074/jbc.M802394200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The plasma form of platelet-activating factor (PAF) acetylhydrolase (PAF-AH), also known as lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) inactivates potent lipid messengers such as PAF and modified phospholipids generated in settings of oxidant stress. In humans, PAF-AH circulates in blood in fully active form and associates with high and low density lipoproteins (HDL and LDL). Several studies suggest that the location of PAF-AH affects both the catalytic efficiency and the function of the enzyme in vivo. The distribution of PAF-AH among lipoproteins varies widely among mammals. Here, we report that mouse and human PAF-AHs associate with human HDL particles of different density. We made use of this observation in the development of a binding assay to identify domains required for association of human PAF-AH with human HDL. Sequence comparisons among species combined with domain-swapping and site-directed mutagenesis studies led us to the identification of C-terminal residues necessary for the association of human PAF-AH with human HDL. Interestingly, the region identified is not conserved among PAF-AHs, suggesting that PAF-AH interacts with HDL particles in a manner that is unique to each species. These findings contribute to our understanding of the mechanisms responsible for association of human PAF-AH with HDL and may facilitate future studies aimed at precisely determining the function of PAF-AH in each lipoprotein particle.
引用
收藏
页码:17099 / 17106
页数:8
相关论文
共 62 条
[51]  
STAFFORINI DM, 1987, J BIOL CHEM, V262, P4215
[52]  
STREMLER KE, 1989, J BIOL CHEM, V264, P5331
[53]  
STREMLER KE, 1991, J BIOL CHEM, V266, P11095
[54]   Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity [J].
Tambaki, AP ;
Rizos, E ;
Tsimihodimos, V ;
Tselepis, AD ;
Elisaf, M .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2004, 9 (02) :91-95
[55]   HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice [J].
Theilmeier, G ;
De Geest, B ;
Van Veldhoven, PP ;
Stengel, D ;
Michiels, C ;
Lox, M ;
Landeloos, M ;
Chapman, MJ ;
Ninio, E ;
Collen, D ;
Himpens, B ;
Holvoet, P .
FASEB JOURNAL, 2000, 14 (13) :2032-2039
[56]  
TSAOUSSIS V, 1994, J LIPID MEDIAT CELL, V9, P317
[57]   PAF-DEGRADING ACETYLHYDROLASE IS PREFERENTIALLY ASSOCIATED WITH DENSE LDL AND VHDL-1 IN HUMAN PLASMA - CATALYTIC CHARACTERISTICS AND RELATION TO THE MONOCYTE-DERIVED ENZYME [J].
TSELEPIS, AD ;
DENTAN, C ;
KARABINA, SAP ;
CHAPMAN, MJ ;
NINIO, E .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1995, 15 (10) :1764-1773
[58]  
Tselepis AD, 2001, J LIPID RES, V42, P1645
[59]   Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins [J].
Tsimihodimos, V ;
Kakafika, A ;
Tambaki, AP ;
Bairaktari, E ;
Chapman, MJ ;
Elisaf, M ;
Tselepis, AD .
JOURNAL OF LIPID RESEARCH, 2003, 44 (05) :927-934
[60]  
Tsimihodimos V, 2002, J LIPID RES, V43, P256